Oral Presentation to Present Updated Data from Phase 2 Trial Demonstrating Successful Transition of Patients from Oral Tacrolimus to TFF TAC Oral Presentation to Present Updated Data from Phase 2 Trial Demonstrating Successful Transition of Patients from Oral Tacrolimus to TFF TAC
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting
